Jennifer Morrissette, PhD, Clinical Director of Penn’s Center for Personalized Diagnostics, evaluates the current status of next generation genomic sequencing for the hematologic malignancies and solid tumor cancers. After reviewing the actionable mutations in the lung cancers, Dr. Morrissette examines the mechanisms of resistance, and offers a glimpse of the future in liquid biopsies.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED